Trials / Completed
CompletedNCT01950299
Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)
Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Virginia Commonwealth University · Academic / Other
- Sex
- All
- Age
- 21 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days.
Detailed description
VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI) measuring the effects on the acute rise and fall of the plasma C reactive protein levels during the first 14 days
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anakinra 100 mg | Anakinra 100 mg starting immediately and then every 24 hours |
| DRUG | Anakinra 100 mg | Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours) |
| DRUG | Placebo | Placebo 0.67 ml injections twice daily |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2018-12-23
- Completion
- 2018-12-23
- First posted
- 2013-09-25
- Last updated
- 2019-12-18
- Results posted
- 2019-12-18
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01950299. Inclusion in this directory is not an endorsement.